Firefly Neuroscience Return on Equity (ROE) Growth & History (AIFF)
Firefly Neuroscience's return on equity was −547.56% for fiscal 2025.
View full Firefly Neuroscience company overviewFirefly Neuroscience annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −547.56% | — |
| 2022 | 2022-12-31 | −233.37% | −221.49 pp |
| 2021 | 2021-12-31 | −11.88% | −41.66 pp |
| 2020 | 2020-12-31 | 29.78% | +77.05 pp |
| 2019 | 2019-12-31 | −47.27% | −44.56 pp |
| 2018 | 2018-12-31 | −2.71% | −16.69 pp |
| 2017 | 2017-12-31 | 13.98% | +43.04 pp |
| 2016 | 2016-12-31 | −29.07% | −32.74 pp |
| 2015 | 2015-12-31 | 3.67% | +5.09 pp |
| 2014 | 2014-12-31 | −1.42% | +1.41 pp |
| 2013 | 2013-12-31 | −2.83% | −7.63 pp |
| 2012 | 2012-12-31 | 4.80% | −3.03 pp |
| 2011 | 2011-12-31 | 7.83% | — |
Firefly Neuroscience quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −17.17% | +4.04 pp |
| Q1 2026 | 2026-03-31 | −24.93% | +512.70 pp |
| Q4 2025 | 2025-12-31 | −28.68% | — |
| Q3 2025 | 2025-09-30 | −24.26% | — |
| Q2 2025 | 2025-06-30 | −21.21% | +491.03 pp |
| Q1 2025 | 2025-03-31 | −537.63% | −414.16 pp |
| Q2 2024 | 2024-06-30 | −512.24% | −585.34 pp |
| Q1 2024 | 2024-03-31 | −123.46% | +1734.46 pp |
| Q2 2023 | 2023-06-30 | 73.11% | +83.14 pp |
| Q1 2023 | 2023-03-31 | −1,857.93% | −1845.39 pp |
| Q4 2022 | 2022-12-31 | −181.65% | −169.96 pp |
| Q3 2022 | 2022-09-30 | −34.38% | −32.13 pp |
| Q2 2022 | 2022-06-30 | −10.03% | −11.67 pp |
| Q1 2022 | 2022-03-31 | −12.54% | −26.00 pp |
| Q4 2021 | 2021-12-31 | −11.70% | −37.05 pp |
| Q3 2021 | 2021-09-30 | −2.25% | −21.55 pp |
| Q2 2021 | 2021-06-30 | 1.64% | +5.04 pp |
| Q1 2021 | 2021-03-31 | 13.46% | +24.95 pp |
| Q4 2020 | 2020-12-31 | 25.36% | +36.61 pp |
| Q3 2020 | 2020-09-30 | 19.29% | +32.19 pp |
| Q2 2020 | 2020-06-30 | −3.40% | +9.78 pp |
| Q1 2020 | 2020-03-31 | −11.49% | −0.77 pp |
| Q4 2019 | 2019-12-31 | −11.25% | −9.14 pp |
| Q3 2019 | 2019-09-30 | −12.90% | −14.38 pp |
| Q2 2019 | 2019-06-30 | −13.18% | −12.87 pp |
| Q1 2019 | 2019-03-31 | −10.73% | −8.96 pp |
| Q4 2018 | 2018-12-31 | −2.11% | −6.38 pp |
| Q3 2018 | 2018-09-30 | 1.48% | −4.83 pp |
| Q2 2018 | 2018-06-30 | −0.31% | −5.71 pp |
| Q1 2018 | 2018-03-31 | −1.77% | +0.19 pp |
| Q4 2017 | 2017-12-31 | 4.27% | +12.52 pp |
| Q3 2017 | 2017-09-30 | 6.31% | +9.49 pp |
| Q2 2017 | 2017-06-30 | 5.39% | +13.08 pp |
| Q1 2017 | 2017-03-31 | −1.96% | +8.19 pp |
| Q4 2016 | 2016-12-31 | −8.25% | −26.09 pp |
| Q3 2016 | 2016-09-30 | −3.18% | +2.05 pp |
| Q2 2016 | 2016-06-30 | −7.68% | −2.81 pp |
| Q1 2016 | 2016-03-31 | −10.15% | −6.01 pp |
| Q4 2015 | 2015-12-31 | 17.84% | +7.73 pp |
| Q3 2015 | 2015-09-30 | −5.23% | −6.73 pp |
| Q2 2015 | 2015-06-30 | −4.87% | +3.46 pp |
| Q1 2015 | 2015-03-31 | −4.14% | +0.59 pp |
| Q4 2014 | 2014-12-31 | 10.11% | +9.15 pp |
| Q3 2014 | 2014-09-30 | 1.50% | −3.86 pp |
| Q2 2014 | 2014-06-30 | −8.34% | −1.62 pp |
| Q1 2014 | 2014-03-31 | −4.73% | −2.28 pp |
| Q4 2013 | 2013-12-31 | 0.96% | −0.36 pp |
| Q3 2013 | 2013-09-30 | 5.36% | +3.28 pp |
| Q2 2013 | 2013-06-30 | −6.71% | −9.23 pp |
| Q1 2013 | 2013-03-31 | −2.46% | −1.34 pp |
| Q4 2012 | 2012-12-31 | 1.32% | −1.27 pp |
| Q3 2012 | 2012-09-30 | 2.07% | −1.16 pp |
| Q2 2012 | 2012-06-30 | 2.51% | +0.03 pp |
| Q1 2012 | 2012-03-31 | −1.11% | — |
| Q4 2011 | 2011-12-31 | 2.59% | — |
| Q3 2011 | 2011-09-30 | 3.23% | — |
| Q2 2011 | 2011-06-30 | 2.49% | — |
Firefly Neuroscience return on equity trends
Over the last five fiscal years, Firefly Neuroscience's return on equity decreased from 29.78% to −547.56%, a change of −577.35 percentage points. The latest reported quarter, Q2 2026, shows −17.17%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Firefly Neuroscience source filings ↗